Methods and compositions for inhibiting CD14 mediated cell activation
AssigneeThe Scripps Research Institute
InventorsDidier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
Life of this patent
Estimating the term…
Abstract
This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.
Claims3
A method of inhibiting cytokine release from CD14+ cells, comprising contacting CD14+ cells with a monoclonal antibody produced by a hybridoma cell of a hybridoma cell line selected from the group consisting of ATCC HB1163, ATCC HB11364, and ATCC HB111637, wherein the antibody is specifically reactive with cell surface CD14, thereby inhibiting cytokine release.
A hybridoma cell line selected from the group consisting of American Type Culture Collection (ATCC™) HB11363, ATCC™ HB11364 and ATCC™ HB11637.
Dependencies are inferred from the claim text.